Trials / Completed
CompletedNCT00141518
Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact
A Long-term Health Economics Study of Intraduodenal Levodopa (Duodopa®) in Routine Care for Patients With Advanced Idiopathic Parkinson's Disease With Severe Motor Fluctuations and Hyper-/Dyskinesia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to collect health economic data depicting the initial levels and natural progression over time of resource usage, Parkinson's disease (PD)-related costs, and health related quality of life (HRQoL) for a cohort of advanced PD patients treated with Duodopa (levodopa-carbidopa in an intestinal gel formulation), of which about one-third were Duodopa-naïve prior to the start of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levodopa-carbidopa intestinal gel (LCIG) | |
| DEVICE | CADD-Legacy® 1400 ambulatory infusion pump | |
| DEVICE | percutaneous endoscopic gastrostomy tube (PEG tube) | |
| DEVICE | jejunal extension tube (J-tube) |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2011-03-01
- Completion
- 2011-04-01
- First posted
- 2005-09-01
- Last updated
- 2016-07-18
- Results posted
- 2016-07-18
Source: ClinicalTrials.gov record NCT00141518. Inclusion in this directory is not an endorsement.